Find cancer before it finds you
Find cancer before it finds you
Detect and eliminate
cancer at its start
Today, the cancer problem is a race against time. Cancer is diagnosed much too late. At least 40% of cancers are diagnosed at advanced or metastatic stage, when available treatments are less effective. Patients suffer moer greatly and are less likely to survive as a result of late diagnosis.
Early diagnosis has been demonstrated to be the most powerful strategy to defeat cancer. By enabling earlier and lighter treatments, early diagnosis avoids suffering, life-altering side effects, and cancer recurrence.
Innovative test captures early cancer signals
Rarecells has been working for more than 10 years in the field of liquid biopsy, developing non-invasive tests targeting early cancer detection. We have developed a unique CE-IVD certified technology (ISET®) to discover very early signals of cancer in blood: circulating tumor cells (CTCs).
CTCs and circulating tumor DNA (ctDNA) are well-established cancer markers. The next-generation ISET® technology enables Rarecells to combine analysis of DNA from CTCs (CTC-DNA) and ctDNA from the same blood draw for a more complete tumor profile and high sensitivity at early stages of cancer.
Rarecells is also partnering with diagnostic and pharma companies to bring its innovative tests to patients.
Our passion
for transforming cancer care
Rarecells has a talented and dedicated team who is developing highly sensitive cancer tests that identify and analyze cancer cells. The idea that we can transform cancer care through early detection drives us every day.
Rarecells’ original research was conducted in France. The company is now established in the United States, with clinical collaborations with leading universities and research centers.
Working with researchers to revolutionize cancer care
Across the globe, researchers are doing amazing work to better understand how to defeat cancer. They universally agree on what is now demonstrated by facts: earlier cancer detection is the safest and most effective strategy to eliminate cancer and save lives.
At Rarecells, we are physicians and scientists using clinical experience and scientific first-in-class innovation to develop life-saving tests and bring them to patients. By leveraging state-of-the-art methods in DNA sequencing and circulating tumor cells detection, all powered by artificial intelligence, we have proven that cancer can be found at very early stages and definitively eliminated.
With more than 125 independent publications, Rarecells’ ISET® technology is a unique, reliable and scientifically proven technology in the field of liquid biopsy, with demonstrated efficacy for all types of cancer.